Abstract：Objective To explore clinical effect ofⅠcotinib in treatment of epidermal growth factor receptor(EGFR) sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensitive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number,34 cases in each group.Group A were givenⅠcotinib treatment,patients in group B were were given Gefitinib treatment,overall effective rate,benefit rate,physical status score and incidence of adverse reactions in two groups were compared and observed.Results Overall effective rate was 82.4%in group A,with 76.5%in group B,and the difference was statistically significant(P＜0.05); 1 year benefit rate and physical status score in group A were slightly better than those in group B,and the difference was not statistically significant(P＞0.05),2 years benefit rate was similar between two groups and had no statistical difference(P＞0.05);incidence of adverse reactions in group A were lower than those in group B(P＜0.05).ConclusionⅠcotinib in treatment of EGFR sensitive mutation in patients with advanced non-small cell lung cancer has significant effect,and less adverse reactions,it is worthy of clinical promotion.
孙勇. 埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析[J]. 中国当代医药, 2016, 23(30): 59-61.
SUN Yong. Clinical analysis of Icotinib in treatment of epidermal growth factor receptor sensitive mutations in advanced non small cell lung cancer benefit. 中国当代医药, 2016, 23(30): 59-61.
京公网安备 11010502046607号